Table 1.
Baseline characteristics of IPF patients enrolled into the EMPIRE registry, overall and accoding to time from diagnosis to registry enrollment
| All patients | Time from diagnosis to enrollment < 6 months | Time from diagnosis to enrollment ≥6 months | |
|---|---|---|---|
| Characteristics | n = 1620 | n = 1213 (74.9%) | n = 407 (25.1%) |
| Country, n (%) | |||
| Austria | 26 (1.6) | 10 (0.8) | 16 (3.9) |
| Bulgaria | 3 (0.2) | 2 (0.2) | 1 (0.2) |
| Croatia | 40 (2.5) | 32 (2.6) | 8 (2.0) |
| Czech Republic | 683 (42.2) | 591 (48.7) | 92 (22.6) |
| Hungary | 112 (6.9) | 89 (7.3) | 23 (5.7) |
| Israel | 78 (4.8) | 41 (3.4) | 37 (9.1) |
| Poland | 255 (15.7) | 125 (10.3) | 130 (31.9) |
| Serbia | 55 (3.4) | 38 (3.1) | 17 (4.2) |
| Slovakia | 110 (6.8) | 87 (7.2) | 23 (5.7) |
| Turkey | 258 (15.9) | 198 (16.3) | 60 (14.7) |
| Time from diagnosis to enrollment [years], mean (SD) | 0.8 (2.0) | 0.1 (0.1) | 3.1 (3.0) |
| Duration of symptoms prior to diagnosis [years], mean (SD) | 1.6 (2.1) | 1.6 (1.8) | 1.5 (2.7) |
| Age at diagnosis [years], mean (SD) | 67.6 (8.9) | 68.4 (8.6) | 65.4 (9.5) |
| Male sex, n (%) | 1157 (71.4) | 878 (72.4) | 279 (68.6) |
| BMI [kg/m2], mean (SD) | 28.4 (4.4) | 28.5 (4.4) | 28.1 (4.5) |
| History of smoking, n (%) | 1019 (62.9) | 767 (63.2) | 252 (61.9) |
| Familial IPF, n (%) | 55 (3.4) | 44 (3.6) | 11 (2.7) |
| Diagnosis based on, n (%) | |||
| Clinical signs | 1286 (79.4) | 988 (81.5) | 298 (73.2) |
| Radiological patterns | 1590 (98.2) | 1194 (98.4) | 396 (97.3) |
| Histopathological patterns | 349 (21.5) | 261 (21.5) | 88 (21.6) |
| FEV1 [% predicted], mean (SD) a | 86.5 (17.2) | 86.4 (16.8) | 87.1 (18.2) |
| FVC [% predicted], mean (SD) a | 78.7 (19.7) | 77.3 (19.4) | 82.7 (19.7) |
| TLCO [% predicted], mean (SD) a | 46.3 (20.9) | 46.6 (20.6) | 45.5 (21.6) |
| 6MWD [m], mean (SD) a | 388.2 (111.0) | 387.7 (109.2) | 389.6 (115.8) |
| GAP stage, n (%) | |||
| I | 772 (47.7) | 536 (44.2) | 236 (58.0) |
| II | 710 (43.8) | 565 (46.6) | 145 (35.6) |
| III | 138 (8.5) | 112 (9.2) | 26 (6.4) |
| Treatment (current or past), n (%) | |||
| Pharmacological | 618 (38.1) | 410 (33.8) | 208 (51.1) |
| Clinical trial | 111 (6.9) | 53 (4.4) | 58 (14.3) |
| Rehabilitation | 427 (26.4) | 352 (29.0) | 75 (18.4) |
| LTOT | 327 (20.2) | 218 (18.0) | 109 (26.8) |
Abbreviations: 6MWD 6-min walk distance, BMI body mass index, FEV1 forced expiratory volume, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, LTOT long-term oxygen therapy, SD standard deviation, TLCO carbon monoxide transfer factor
aIf measurement was not available at enrollment, data measured at diagnosis were used